Relapsed or Refractory Peripheral T-Cell Lymphoma (R/R PTCL) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Relapsed or Refractory Peripheral T-Cell Lymphoma Emerging Therapy and TPP Insights

Thelansis’s “Relapsed or Refractory Peripheral T-Cell Lymphoma (R/R PTCL) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Relapsed or Refractory Peripheral T-Cell Lymphoma Overview

Relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) describes diverse T-cell malignancies that persist after treatment or return following response. Biology varies by subtype and may involve alterations in epigenetic regulators and JAK/STAT, T-cell receptor or other signalling pathways. Patients may develop enlarging lymph nodes, extranodal disease, fever, night sweats, weight loss and cytopenias. Treatment depends on histology, CD30/ALK status, prior therapy, fitness and transplant eligibility. Clinical-trial enrolment is preferred where possible; otherwise, non-cross-resistant salvage regimens such as ICE, DHAP or GDP may be used. Brentuximab vedotin is an option for relapsed systemic anaplastic large-cell lymphoma, while pralatrexate and belinostat are approved in the US for previously treated PTCL. Responders eligible for transplantation may proceed to HSCT, preferably allogeneic if not used previously. Short remissions and limited durable options remain major challenges.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)